Supplementary Fig. S2 from The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin

Dellavedova, Giulia; Decio, Alessandra; Formenti, Laura; Albertella, Mark R.; Wilson, Joanne; Staniszewska, Anna D.; Leo, Elisabetta; Giavazzi, Raffaella; Ghilardi, Carmen; Bani, Maria Rosa

doi:10.1158/2767-9764.22361312.v1

crc-22-0423-s02.pdf (627.39 kB)

Supplementary Fig. S2 from The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin

journal contribution

posted on 2023-03-30, 11:46 authored by Giulia Dellavedova, Alessandra Decio, Laura Formenti, Mark R. Albertella, Joanne Wilson, Anna D. Staniszewska, Elisabetta Leo, Raffaella Giavazzi, Carmen Ghilardi, Maria Rosa Bani

Figure S2 shows the response of the OC-PDXs to platinum and olaparib

Funding

Associazione Italiana per la Ricerca sul Cancro (AIRC)

History

ARTICLE ABSTRACT

Selective PARP1i AZD5305 can exceed the efficacy of first-generation PARPi, which target both PARP1 and PARP2, and potentiates the efficacy of CPT when given in combination. AZD5305 alone or in combination with platinum delayed visceral metastasis, ultimately extending the lifespan of OC-PDX–bearing mice. These preclinical models mimic the progression of the disease occurring in patients after debulking surgery, and are translationally relevant.